Abbott Completes Acquisition of Tendyne Holdings, Inc.
ABBOTT PARK, Ill.,
"The Tendyne acquisition broadens Abbott's foundation as a leader in treatments for mitral valve disease, which is highly complex and requires multiple treatment options," said
Tendyne's Bioprosthetic Mitral Valve System is designed to be implanted in a beating heart, without the need for open heart surgery, which would be a new treatment option for mitral valve replacement. It is an investigational device and not currently available for sale.
Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 73,000 people.
Visit Abbott at www.abbott.com and connect with us on Twitter at @AbbottNews.
Private Securities Litigation Reform Act of 1995 – A Caution Concerning Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/abbott-completes-acquisition-of-tendyne-holdings-inc-300136563.html
Abbott Media: Steve Kelly, (408) 845-3427, or Mira Jang, (408) 250-5782; Abbott Financial: Scott Leinenweber, (224) 668-0791